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Introduction 
The first case of coronavirus disease 2019 (COVID-19) 
was diagnosed on December 8, 2019, in Wuhan city of 
central China.[1] It is a severe acute respiratory 
syndrome (SARS) caused by the SARS-CoV-2 
coronavirus. The World Health Organization (WHO) 
declared the COVID-19 outbreak as a pandemic on 
March 11, 2020. More than 12.5 million confirmed 
cases and over 550,000 deaths have been reported 
worldwide, as of July 12, 2020.[2]. Neurological 
manifestations in COVID-19 have been reported from 
early features of anosmia and dysgeusia to widespread 
involvement of the central nervous system (CNS), 
peripheral nervous system (PNS), and the muscle.[3] 
Multiple studies have suggested an increased 
propensity among COVID-19 patients to systemic 
thromboembolism.[4-6] An increase in cerebrovascular 
diseases (1-6%) has also been reported among 
COVID-19 patients.[7] However, the available data 
regarding the cerebral venous sinus thrombosis (CVST) 
in COVID-19 patients is generally limited. The purpose 
of this article is to review the available literature 
regarding the CVST cases in COVID-19 patients and 
look for a possible correlation. 
MATERIALS AND METHODS:
An online literature search was conducted through the 
Medline (PubMed) database. We used the following 
search keywords terms: “CVST” or “CVT” or “cerebral 
venous thrombosis” or “cerebral venous sinus 
thrombosis” and “COVID-19” or “coronavirus”. We 
included the articles that were published in English and 
published from 1st January 2020 to 30th June 2020. 
Our search retrieved a total of 20 results. 7 results out 
of 20 were excluded due to unrelated title and abstract, 
short commentaries, and duplicate results. Finally, 13 
full-text articles were included in this review.
RESULTS
A total of seven case reports and two case series were 
included in this review. Both case series consisted of a 
total of five cases, making the total subject count to 
12. All cases tested positive for SARS-CoV-2 by reverse 
transcriptase-polymerase chain reaction (RT PCR) 
assay of a nasopharyngeal swab. Out of 12 subjects, 7 
were male (58%) and 5 were female (42%). The 
average age was 52.2 years with a range of 23-81 
years. In 9 out of 12 cases, the diagnosis of CVST was 
confirmed by a venogram, while in the remaining 3 
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patients the diagnosis of CVST was suspected based on 
the characteristic CT and/or MRI findings.[8-10] One case 
had concomitant arterial and venous thrombosis.[9] Two 
female cases were on oral contraceptives,[8,10] one 
female was on hormonal therapy for breast cancer,[11] 
and one male case had a history of ocular myasthenia, 
prostate adenocarcinoma, and B-cell chronic 
lymphocytic leukemia.[9] Headache and altered 
mentation (67%) were the most common neurological 
features among these patients, followed by 
hemiparesis (33%), aphasia (25%), and seizures (17%) 
with one case having status epilepticus (8%). Five 
cases (42%) presented with either headache or altered 
mentation or both.[8,9,11,13] Four patients (33%) did not 
have respiratory symptoms at the time of diagnosis of 
CVST.[8,10,12,13] A clinical outcome of 8 cases has been 
mentioned. Five out of eight cases (62%) died while 
three cases (38%) were discharged home with 
improving conditions (Table 1).
DISCUSSION
COVID-19 is a novel infection that primarily affects the 
respiratory system but it is known to affect almost all 
the systems of our body, including the nervous system. 
The most common reported neurological 
manifestations of COVID-19 patients are anosmia (5.1 
% – 85.6%) and dysgeusia (5.6% - 88%) followed by 
headache (8%) and dizziness (7-9%).[3] 
Cerebrovascular diseases (1% - 6%) are also reported 
in COVID-19 patients especially with the severe 
COVID-19 disease (2.5-fold increase in odds).[7] 
Ischemic stroke mainly from large-vessel occlusion is 
the most commonly reported type of cerebrovascular 
disease.[7] A similar pooled data regarding the CVST is 
presently lacking. Hypercoagulable state is one of the 
important risk factors for CVST.[17] COVID-19 may also 
predispose the patients to a systemic hypercoagulable 
state. In a retrospective study, a 31% incidence of 
thrombotic complications is reported in Dutch patients 
(n=184) with severe COVID-19 admitted in the 
intensive care unit (ICU) including 3 patients with 
stroke, with pulmonary embolism being the most 
common thrombotic complication among them (n=25, 
81%). The independent predictors of thrombotic 
complications in these patients were advanced age and 
coagulopathy, which is defined as spontaneous 
prolongation of PT/APTT (prothrombin time > 3 s or 
activated partial thromboplastin time > 5 s).[4] Another 
retrospective study from Italy (n=388) reported a high 
incidence of venous thromboembolism (21%) in 
COVID-19 patients.[5] In France, a retrospective study 
revealed a higher incidence (11.7%) of thrombotic 
complications in COVID-19 patients with acute 
respiratory distress syndrome (ARDS) (n=150) as 
compared to the control group of non-COVID-19 ARDS 
patients (2.1%).[6] Almost all the patients were 
receiving standard thromboprophylaxis in these studies. 
It is surprising that despite an increased incidence of 
systemic thrombotic complications, no cases of CVST 
were reported in these studies. However, an 
underestimation cannot be excluded.  In our review, 4 
out of 12 patients (33%) already had the risk factors for 
CVST. A thrombophilia workup was only performed for 4 
patients (33%), which was negative.[10,13-15] Due to the 
lack of available data at present, a causal relationship 
between the COVID-19 and CVST cannot be definitely 
made. Five cases (42%) presented with either 
headache or altered mentation or both.[8,9,11,13] 
Therefore, we suggest that there should be a low 
threshold for ordering venogram to exclude CVST in 
COVID-19 patients presenting with headache and/or 
altered mentation. Interestingly, four patients (33%) did 
not have respiratory symptoms at the time of diagnosis 
of CVST.[8,10,12,13] Presuming many patients with 
COVID-19 are asymptomatic, all patients with newly 
diagnosed CVST should undergo a nasopharyngeal 
swab testing for SARS-CoV-2 RT-PCR or a CT scan of 
the chest scan to look for COVID-19 infection in the 
current pandemic situation. 
PATHOPHYSIOLOGY
Multiple pathophysiological mechanisms for 
SARS-CoV-2 infectivity have been proposed. The 
interaction between the SARS-CoV-2 and 
angiotensin-converting enzyme 2 (ACE2) receptors has 
been proposed as one of the important potential 
factors in its infectivity. SARS-CoV-2 gains entry into our 
body through ACE2 receptors and later also 
down-regulates ACE2 expression. ACE2 receptors are 
present in the respiratory tract as well as in the 
endothelial lining of the heart, intestines, kidney, and 
brain.[1,3,18] A direct neuroinvasion through the nasal 
epithelium and olfactory bulb with subsequent 
retrograde spread has been proposed. Netland et al. [19] 
conducted an experiment on transgenic mice 
expressing the human ACE2 receptors and infecting 
them with SARS-CoV. The authors reported viral entry 
into the brain primarily via the olfactory bulb with further 
spread within the CNS. They also reported significant 
neuronal injury with relatively limited inflammation 
suggesting a possibility that inflammatory signs may be 
minimal or even absent in these patients. The detection 
of cerebrospinal fluid RT-PCR for SARS-CoV-2 in a few 
cases [20-21] also hints to the direct neuroinvasion of 
SARS-CoV-2. Another proposed theory is based on the 
findings of viral endotheliitis in the postmortem 
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examinations of COVID-19 patients.[22] The direct viral 
invasion of endothelial cells may cause widespread 
endothelial dysfunction resulting in procoagulant state 
and multiorgan vascular involvement as seen in severe 
COVID-19 infections.[1] Further, severe COVID-19 
infections may also increase the risk for 
thromboembolic disease due to excessive systemic 
inflammation, hypoxia, hypotension and inadequate 
cerebral perfusion, immobilization, and diffuse 
intravascular coagulation, with very high serum levels of 
C reactive protein, D-dimer, ferritin, fibrinogen, and 
fibrinogen degradation product.[1,3] Antiphospholipid 
antibodies (anticardiolipin IgA and antibodies directed 
against β2-glycoprotein-1) have also been found in 
patients with COVID-associated large vessel ischemic 
strokes, which may further increase the risk of 
thrombotic disease.[23]
LIMITATIONS
The main limitation is the small number of available 
cases. We believe that the number of CVST cases are 
an underestimation. Many CVST cases may present 
with nonspecific symptoms such as headache and 
altered mentation, which need to be evaluated in these 
patients. The systemic thrombophilia workup was also 
absent in the majority of the cases. The severe 
COVID-19 patients are also administered multiple 
drugs. The effects of these drugs on coagulation need 
evaluation. Further, the confounders such as 
dehydration and anemia, are not adjusted. They 
independently increase the risk of CVST and are 
commonly present in severely ill patients.
FUTURE DIRECTIONS
We are still learning about the neurology of COVID-19. 
Epidemiological studies are required to provide an 
estimation of the total numbers of CVST cases, 
including the mild ones. The risk factors, drug effects, 
behaviors, and outcomes need to be evaluated. The 
neurotropic potential of SARS-CoV-2 has to be 
understood and the frequency of its complications, 
including but not limiting to the cerebrovascular 
diseases, has to be reported for early diagnosis and 
management.
CONCLUSIONS
The limited data suggest that the COVID-19 may 
predispose patients to CVST secondary to the high 
incidence of systemic thromboembolism. However, 
large studies are needed to confirm a possible causal 
relationship between CVST and COVID-19 infection. We 
suggest a venogram should be performed in COVID-19 
patients presenting with altered mentation and/or 
headache, with or without focal neurological deficits, to 
exclude CVST. Similarly, patients presenting with acute 
CVST in the current pandemic should be evaluated for 
COVID-19.
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AM = Altered mentation; ASD = Autism spectrum disorder; B-CLL = B-cell chronic lymphocytic leukemia; Bil. = Bilateral; BMI = Body mass index; CVST = 
Cerebral venous sinus thrombosis; DCV = Deep cerebral veins; DM = Diabetes mellitus; F = female; HA = Headache; HP = Hemiparesis; HTN = Hypertension;
ICV = Internal cerebral veins; LMWH = Low molecular weight heparin; Lt. = Left;  M = male; MCA = Middle cerebral artery; MG = Myasthenia gravis; N/A = 
not available; PMH = Past medical history; Rt. = Right; TS = Transverse sinus; SS = sigmoid sinus; TURP = Transurethral resection of the prostate
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